MedTrace Logo

Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia

NCT01437202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-07-09

No results posted yet for this study

Summary

This is a multicenter, retrospective, observational study to validate a pharmacogenetics model for imatinib metabolism and resistance in patients with chronic myeloid leukemia among patients in different independent cohort.

Conditions

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Jong Won Kim, MD, PhD · Samsung Medical Center, Sungjyunkwan University School of Medicine, Seoul, Korea

  • Dae-Young Kim, MD · Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-09-30
Completion
2012-10-31

Countries

  • Canada
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01437202 on ClinicalTrials.gov